The European Board Certificate in Nuclear Medicine proves that
the candidate’s knowledge and ability in Nuclear Medicine s...
Certificate of Fellowship
of the European Board of Nuclear Medicine
APPLICATION FORM 2002
Please fill in this form (type o...
I. Scope and limits of the medical speciality
of nuclear medicine
1. Definition (scope):
Nuclear Medicine (NM) utilizes th...
3. The trainees should be encouraged to participate
in basic and clinical research work
B. Organization
The quality of the...
The MCQ paper in 2001 consisted of 140 Multiple
Choice Questions. These were taken from the following
Field Codes
Field Co...
8. You receive a request for an infection imaging scan
on an HIV-positive 25-year-old man who was present-
ed to the hospi...
Upcoming SlideShare
Loading in...5
×

Certificate of Fellowship of the European Board of Nuclear ...

11,632

Published on

Published in: Technology, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
11,632
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
7
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Transcript of "Certificate of Fellowship of the European Board of Nuclear ..."

  1. 1. The European Board Certificate in Nuclear Medicine proves that the candidate’s knowledge and ability in Nuclear Medicine satisfy European standards. Candidates: To be awarded a Certificate of Fellowship of the EBNM it is necessary to fulfil the following prerequisites: – having obtained the title of specialist in nuclear medicine before September 1, 1998, in a European country being full or asso- ciate member of UEMS – having proof of continuing education following national accred- itation – pass the full Fellowship Examination. Candidates may enrol for and take the written exam (multiple choice questions) only after they have been awarded their special- ist qualification by their national body. According to UEMS regu- lations, however, they cannot undergo the oral examination, nor be awarded the Fellowship, until a minimum of three years after hav- ing received their specialist qualification. Venue: The next examination of the European Board Certificate of Nuclear Medicine will take place at the occasion of the EANM ’02 Congress held in Vienna, August 31 – September 4, 2002. Examination: It will comprise a written part (multiple choice questions) and an oral examination. Only candidates having passed the written part will be admitted to the oral examinations. Language: The multiple choice questions and the oral examina- tion have to be taken in English. In case of difficulties with oral expression in this language, candidates are allowed to ask for the presence, at the oral examination, of an additional examiner famil- iar with the candidate’s language, who will be chosen by the Jury in order to assist the candidate in correct understanding. Applications: Applications have to be sent with a curriculum vi- tae including detailed listing of all institutions where the training was completed, and the names of the head of the departments. A detailed list of the types of procedures performed in nuclear medi- cine according to the Syllabus (EJNM 1998,25:BP9-BP10) has to be attached. Even if training has not been obtained in all proce- dures, candidates can be admitted by the Jury if their experience is considered wide enough, and includes whole body scanning, emis- sion tomography, in vitro tests and therapy. Registration fee: The fee has to be sent following notice of acceptance of the candi- date’s application by the Jury. Only candidates having paid the fee by July 1, 2002 will be accepted for the test. Registration fee for both MCQ and oral examination: ........... E 300 Registration fee for MCQ paper only: ....................................E 200 Oral examination only - provided the written test has been previously passed: ................................................E 150 Refund Policy: Registration fees less EUR 30 processing fee will be refunded if a written request is received prior to August 1, 2002 Important dates: Deadline for application May 17, 2002 Notification by the Board June 15, 2002 Payment of registration fees July 1, 2002 Refund in case of cancellation August 1, 2002 Written examination August 31, 2002 * Oral examination September 2, 2002 * (* Dates to be confirmed) For further information, please contact: Prof. A. Bischof Delaloye, Service de Médecine nucléaire, Centre Hospitalier Universitaire Vaudois, CH-1011 Lausanne, Switzerland Phone: (+41) 21 314 43 46 Fax (+41) 21 314 43 49 E-mail angelika.bischofdelaloye@chuv.hospvd.ch Certificate of Fellowship of the European Board of Nuclear Medicine 2002 INFORMATION Eur J Nucl Med (2002) 29:BP5–BP6 Vol. 29, No. 4, April 2002 – © EANM 2002
  2. 2. Certificate of Fellowship of the European Board of Nuclear Medicine APPLICATION FORM 2002 Please fill in this form (type or write in block letters) and return it before May 17, 2002 to: EANM Executive Secretariat, Lassingleithnerplatz 2/3, A-1020 Vienna, Austria. Fax: +43 1 212 80 33, e-mail: office@eanm.org CANDIDATE ❑ Prof ❑ Dr ❑ Mr ❑ Mrs other title: _________________________ Family Name: ______________________________________ First Name ___________________________________ Address: ___________________________________________________________________________________________ City: ________________________________ Postal Code: ___________ Country: __________________________ Tel. No: ______________________________ Fax No: _____________________ e-mail: ______________________ Date of the National Board Certificate: .............................................................................................................................. LANGUAGE (chosen for the oral examination) ❑ English ❑ French ❑ German ❑ I have difficulties with oral expression in English and I ask for the presence of an additional examiner familiar with my language, which is ..................................................................................... ENCLOSURES ❑ curriculum vitae / list of training institutions, including names of heads of departments ❑ copies of certificates ❑ detailed list of performed nuclear medicine procedures according to the Syllabus ❑ detailed description of continuing education after national accreditation (credits) ❑ certificate of successfully passed MCQ – to be sent if applying only for the oral examination REGISTRATION AND PAYMENT (tick appropriate box) Registration fee for both MCQ and oral examination: .................................................... ❑ E 300 Registration fee for MCQ paper only: ............................................................................ ❑ E 200 Registration fee for oral examination (date of successfully passed MCQ ................... ) ❑ E 150 FORM OF PAYMENT: ❑ Bank transfer to EANM bank account: (all charges for the ordering customer) Erste Österreichische Sparkasse, Taborstrasse 26, A-1020 Vienna Account Number: 021-50077 Bank Code: 20111 Swift Code: GI BA AT WW IBAN: AT592011100002150077 ❑ Credit Card ❑ American Express ❑ Visa ❑ Master/Eurocard Credit Card Number: ....................................................................................................................................................... Expiry Date: ....................................... Name of Cardholder: ...................................................................................... Signature of Cardholder: ................................................................................................................................................. Cancellation: Registration fees less E 30 processing fee will be refunded if a written request is received by August 1, 2002 Date: _____________________________ Signature: ____________________________________________________ BP6 European Journal of Nuclear Medicine Vol. 29, No. 1, January 2002
  3. 3. I. Scope and limits of the medical speciality of nuclear medicine 1. Definition (scope): Nuclear Medicine (NM) utilizes the nuclear properties of matter to investigate disorders of metabolism and func- tion, of physiology and pathophysiology, and of anatomy to diagnose disease with unsealed sources and to treat it with unsealed sources of radioactivity. The range of ac- tivities that are implicit within this definition include in vitro procedures, in vivo imaging with radiopharmaceu- ticals and other techniques related to nuclear physics in medicine as well as the medical applications of radiobi- ology, dosimetry and radiation protection. 2. Clinical knowledge and experience: A good general background in medicine (internal medi- cine, surgery) is assumed. More detailed knowledge is required of those conditions which may need to be inves- tigated or treated by NM techniques. 3. NM may also make use of complementary methods insofar as these relate to NM procedures. These may include: – Ultrasound – ECG (incl. dynamic + pharmacological stress testing) and management of emergencies in cardiac nuclear medicine – Fine-needle biopsy – Quantitative imaging: MRT, MRS and correlative im- aging methods – Spirometry – Non-radioactive laboratory assays – Bone densitometry – Other available techniques complementary to NM procedures 4. NM specialists may cooperate in the assessment, prevention and treatment of physical or medical accidental contamination or incorporation of radionuclides II. Basic sciences training A. Syllabus 1. Nuclear physicians have to be familiar with and have knowledge of: – Physics (as applied to NM) – Biostatistics – Pharmacology – Radiochemistry – Radiopharmacy – Biokinetics – Radiobiology and risk assessment – Radioprotection – Computer science – Instrumentation and methodology – Quality control – Relevant legislation 2. Nuclear physicians must have gained practical experience in: – Methods of clinical investigation – Labelling (including cell labelling) – Software application and data acquisition and analysis – Quality control: a) Gamma cameras (including SPET) and other NM devices b) Radiopharmaceuticals – Patient dosimetry (diagnosis and therapy) – Radiation protection (decontamination, waste disposal, staff dosimetry etc.) EBNM Syllabus for post-graduate specialisation in Nuclear Medicine The Syllabus Committee of The European Board of Nuclear Medicine UEMS Specialist Section of Nuclear Medicine Eur J Nucl Med (2002) 29:BP7–BP8 Vol. 29, No. 4, April 2002 – © EANM 2002
  4. 4. 3. The trainees should be encouraged to participate in basic and clinical research work B. Organization The quality of the basic science training has to be objec- tively assessed, using the following methods: 1. Final examination (covering basic science and clinical skills) on a national basis and/or 2. Satisfactory completion of accredited, regional or na- tional (international) courses or workshops in differ- ent fields (physics etc.): 120 hours recommended. Courses on radiation protection and regulation issues are not included, due to different national rules. 3. Practical training has to be added to the courses and has to be formally controlled. III. Clinical training The clinical training of physicians specializing in NM should include theoretical and clinical training within and outside of the Nuclear Medicine Department. Mini- mum standards are indicated here. 1. Theoretical grounding in NM A minimum of 30 hours of formal description of general principles of NM procedures is required. Active partici- pation in clinical presentations, seminars and meetings is recommended. 2. In vivo diagnostic procedures Responsibility (including indication, performance and interpretation) must be taken for a sufficient number of various in vivo NM diagnostic procedures. A total of 3,000 documented procedures must be reached by the trainee. The minimum recommended number for each procedure is as follows: No. of studies a) Central nervous system 100 (80% SPET or PET) b) Skeletal system 750 c) Cardiovascular system 500 (50% SPET or PET) d) Pulmonary system 300 (50% combined V/Q) e) Gastrointestinal system 150 f) Urogenital system 400 g) Endocrine system 400 h) Haematopoietic and 50 lymphatic systems i) Tumours and inflammation 300 (50% SPET or PET) (including gallium, thallium, immunoscintigraphy etc.) j) Other studies 50 Some flexibility may be accepted, but a broad spectrum of most currently used procedures has to be covered. This list will be subject to periodic revision. It is recommended that a period of training is spent away from the main de- partment in at least one other recognized training centre. 3. Clinical training in addition to NM Clinical bedside training in a clinical specialty is re- quired before or during specialist training. A limited pe- riod of 6 months in diagnostic radiology or clinical phys- iology may replace a clinical bedside semester. The proportion of the total training period devoted to clinical training and to NM may vary according to vari- ous factors, including the total length of the training. The minimum advisable duration of training is 5 years. In this case a minimum of 3 years should be devoted to NM and 2 years to other specialties. In those countries where the total duration of the spe- cialized training is 4 years (which corresponds to the minimum duration in the Directive of the EC), 3 years should be devoted to NM and 1 year to other specialties. 4. In vitro procedures Training can also cover analysis with (radio)-immuno- logical methods, quality control and interpretation. In this case a minimum of 3 months’ training should be giv- en. 5. Therapy Training should include indications, administration, ther- apeutic applications of radionuclides, dosimetry, radia- tion protection and follow-up of therapeutic activities of radionuclides. The trainee must have taken part in a sufficient num- ber of various NM therapeutic procedures, as indicated: Patients treated Thyroid patients Benign disease 60 Malignant disease 20 Other radionuclide therapy 10 6. Clinical audit The trainee should have received education in audit of clinical NM and in the administration and financing of an NM Service. 7. Function as expert The trainee must acquire legal expertise in health care problems due to unsealed radionuclides. BP8 European Journal of Nuclear Medicine Vol. 29, No. 1, January 2002
  5. 5. The MCQ paper in 2001 consisted of 140 Multiple Choice Questions. These were taken from the following Field Codes Field Codes No Bone 13 Cardiovascular 14 Endocrinology 15 Gastroenterology 9 Haematology 4 Iinfection 7 Lung 9 Nephro-Urology 9 Neurology 9 Oncology/Radiat. Therapy 18 Paediatrics 5 Physics/Instrumentation 13 Radiobiology 4 Radiopharmacy/Radiochem. 11 Total 140 Examples of the questions are given below. In all cases there is only one correct answer. Further examples from previous years were published in the Blue Pages of the Eur J Nucl Med 1998; 25:BP1-BP2 and 1999; 26:BP11-BP12. 1. A bone scan showing unusual concentration of Tc-99m-diphosphonate in the outer aspect of the glu- teal area might be due to any of the following, except: a) Polymyalgia rheumatica b) An intramuscular injection of a medication previ- ously given c) A localised abscess d) Skin contamination of urine e) Soft tissue calcification 2. Which of the following represents an advantage of adenosine over dipyridamole in myocardial perfusion scintigraphy? a) Higher sensitivity b) Higher specificity c) Adenosine has a shorter half time d) Adenosine has a longer half time 3. The most frequent late effect of I-131 therapy for thy- roid carcinoma is: a) Infertility b) Salivary gland dysfunction c) Leukaemia d) Bladder cancer 4. In Tc-99m-MIBI imaging of suspected parathyroid adenomas: a) It is essential to localise the thyroid separately with Tc-99m pertechnetate or I-123 b) Localisation of glands may be improved by SPECT c) Optimal imaging time is 15 minutes post injection d) Imaging can be limited to the neck in all patients e) Patients taking thyroxine must stop this 4 weeks before the scan 5. The accuracy of glomerular filtration rate (GFR) mea- surements utilising Tc-99m-DTPA shows systematic errors due to: a) Reabsorption by renal tubules b) Excretion by renal tubules c) The 6 h half-life of Tc-99m d) Protein binding of the radiopharmaceutical 6. Avid gallium-67 uptake is a common feature in all the following except: a) Sarcoidosis b) Mycobacterium tuberculosis c) Kaposi sarcoma d) Non-small cell carcinoma of the lung e) Wegener’s granulomatosis 7. The tracer of choice for indirect radionuclide cystog- raphy in children is: a) Tc-99m-DTPA b) I-131-hippuran c) Tc-99m-DMSA d) Tc-99m-gluconate e) Tc-99m-MAG-3 European Board of Nuclear Medicine Multiple Choice Questions – 2001 Eur J Nucl Med (2002) 29:BP9–BP10 Vol. 29, No. 4, April 2002 – © EANM 2002
  6. 6. 8. You receive a request for an infection imaging scan on an HIV-positive 25-year-old man who was present- ed to the hospital with increasing breathlessness. He has no cough and his chest X-ray was clear. Which specific infection study would you recommend? a) Ga-67 citrate b) In-111 labelled leucocytes c) Tc-99m HMPAO labelled leucocytes d) Tc-99m anti-granulocyte antibodies e) Tc-99m human immunoglobulin (HIG) 9. Which statement is correct? The activity of Mo-99 in the eluate of Tc-99m generator is limited to a very low level because: a) Molybdenum interferes with the reduction of pert- echnetate b) Molybdenum interferes with the formation of some Tc-99m complexes c) Molybdenum interferes with the biodistribution of some Tc-99m radiopharmaceuticals d) Molybdenum-99 delivers an undesirable radiation burden to the patient 10. A pin-hole collimator may be useful in examination of, for instance, small structures and the thyroid. Its main advantage and disadvantage are: a) Better spatial resolution but distance-dependent image size b) Distance-independent spatial resolution but dis- torted linearity c) Higher sensitivity but impaired spatial resolution d) Better linearity but impaired spatial resolution Answers: 1=a, 2=c, 3=b, 4=b, 5=d, 6=c, 7=e, 8=a, 9=d, 10=a BP10 European Journal of Nuclear Medicine Vol. 29, No. 1, January 2002

×